Near-infrared fluorescent aza-BODIPY dye-loaded biodegradable polymeric nanoparticles for optical cancer imaging
Source abstract
Abstract
Nanoparticles are being readily investigated as carriers for the delivery of imaging and therapeutic agents for the detection, monitoring, and treatment of cancer and other diseases. In the present work, the preparation of biodegradable polymeric nanoparticles loaded with a near-infrared fluorescent aza-boron dipyrromethene (NIR-BODIPY) derivative, and their use as contrast agents for optical imaging in cancer are described. Nanoparticles were prepared by nanoprecipitation of amphiphilic block copolymers of poly(lactic acid) and poly(ethylene glycol). The size, morphology, dye loading, spectral properties, quantum yield, cytocompatibility, and in vitro NIR imaging potential of the nanoparticles in breast and ovarian cancer cells were evaluated. Spherical nanoparticles of 30–70 nm in diameter were loaded with 0.73 w/w% BODIPY derivative. At this loading, the dye presented a fluorescence quantum yield in the same order of magnitude as in solution. Nanoparticle suspensions at concentrations up to 580 μg/mL were cytocompatible to breast (MDA-MB-231) and ovarian (SKOV-3 and Caov-3) cancer cells after a four-hour incubation period. Fluorescence microscopy images demonstrated the ability of the nanoparticles to act as imaging agents in all three cell lines in as little as 1 hour. The results shown indicate the potential of these NIR-BODIPY-loaded nanoparticles as contrast agents for near-infrared optical imaging in cancer.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Aydogan F, Ozben V, Aytac E, Yilmaz H, Cercel A, Celik V (2012) Excision of nonpalpable breast cancer with indocyanine green fluorescence-guided occult lesion localization (IFOLL). Breast Care (Basel) 7:48–51. doi: 10.1159/00033649710.1159/000336497 ↗
2. Bao L et al (2011) Electrochemical tuning of luminescent carbon nanodots: from preparation to luminescence mechanism. Adv Mater 23:5801–5806. doi: 10.1002/adma.20110286610.1002/adma.201102866 ↗
3. Benson RC, Kues HA (1978) Fluorescence properties of indocyanine green as related to angiography. Phys Med Biol 23:159–16310.1088/0031-9155/23/1/017 ↗
4. Betancourt T, Brown B, Brannon-Peppas L (2007) Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (London) 2:219–232. doi: 10.2217/17435889.2.2.21910.2217/17435889.2.2.219 ↗
5. Betancourt T et al (2009a) PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J Biomed Mater Res A 91:263–276. doi: 10.1002/jbm.a.3224710.1002/jbm.a.32247 ↗
6. Betancourt T, Shah K, Brannon-Peppas L (2009b) Rhodamine-loaded poly(lactic-co-glycolic acid) nanoparticles for investigation of in vitro interactions with breast cancer cells. J Mater Sci Mater Med 20:387–395. doi: 10.1007/s10856-008-3594-z10.1007/s10856-008-3594-z ↗
7. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626. doi: 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
8. Caldorera-Moore ME, Liechty WB, Peppas NA (2011) Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res 44:1061–1070. doi: 10.1021/ar200177710.1021/ar2001777 ↗
9. Celli JP et al (2010) Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 110:2795–2838. doi: 10.1021/cr900300p10.1021/cr900300p ↗
10. Chi C et al (2014) Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics 4:1072–1084. doi: 10.7150/thno.989910.7150/thno.9899 ↗
11. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. doi: 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
12. Doornbos RM, Lang R, Aalders MC, Cross FW, Sterenborg HJ (1999) The determination of in vivo human tissue optical properties and absolute chromophore concentrations using spatially resolved steady-state diffuse reflectance spectroscopy. Phys Med Biol 44:967–98110.1088/0031-9155/44/4/012 ↗
13. Gresser R, Hummert M, Hartmann H, Leo K, Riede M (2011) Synthesis and characterization of near-infrared absorbing benzannulated aza-BODIPY dyes. Chemistry 17:2939–2947. doi: 10.1002/chem.20100294110.1002/chem.201002941 ↗
14. Hermanson GT (2013) Bioconjugate techniques, 3rd edn. Elsevier Inc., Waltham
15. HORIBA (2012) A guide to recording fluorescence quantum yields. Jobin Yvon Ltd, Stanmore
16. Jiang S, Gnanasammandhan MK, Zhang Y (2010) Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface 7:3–18. doi: 10.1098/rsif.2009.024310.1098/rsif.2009.0243 ↗
17. Khullar O, Frangioni JV, Grinstaff M, Colson YL (2009) Image-guided sentinel lymph node mapping and nanotechnology-based nodal treatment in lung cancer using invisible near-infrared fluorescent light. Semin Thorac Cardiovasc Surg 21:309–315. doi: 10.1053/j.semtcvs.2009.11.00910.1053/j.semtcvs.2009.11.009 ↗
18. Liu Y, Liu C-Y, Zhang Z-Y (2013) Graphitized carbon dots emitting strong green photoluminescence. J Mater Chem C 1:4902–490710.1039/c3tc30670d ↗
19. Loudet A, Burgess K (2007) BODIPY dyes and their derivatives: syntheses and spectroscopic properties. Chem Rev 107:4891–4932. doi: 10.1021/cr078381n10.1021/cr078381n ↗
20. Mahmood U, Weissleder R (2003) Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2:489–496
21. Marshall MV et al (1010) Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. Open Surg Oncol J 2:12–2510.2174/1876504101002020012 ↗
22. Mito JK et al (2012) Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer 118:5320–5330. doi: 10.1002/cncr.2745810.1002/cncr.27458 ↗
23. Nagaich U (2014) Nanomedicine: revolutionary trends in drug delivery and diagnostics. J Adv Pharm Technol Res 5:1. doi: 10.4103/2231-4040.12697710.4103/2231-4040.126977 ↗
24. Narang AS, Varia S (2011) Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 63:640–658. doi: 10.1016/j.addr.2011.04.00210.1016/j.addr.2011.04.002 ↗
25. Ntziachristos V, Ripoll J, Weissleder R (2002) Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt Lett 27:333–33510.1364/OL.27.000333 ↗
26. Ntziachristos V, Bremer C, Weissleder R (2003) Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 13:195–208. doi: 10.1007/s00330-002-1524-x10.1007/s00330-002-1524-x ↗
27. Ozel T, White S, Nguyen E, Moy A, Brenes N, Choi B, Betancourt T (2015) Enzymatically activated near infrared nanoprobes based on amphiphilic block copolymers for optical detection of cancer. Lasers Surg Med 47:579–594. doi: 10.1002/lsm.2239610.1002/lsm.22396 ↗
28. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8:147–166. doi: 10.1016/j.nano.2011.05.01610.1016/j.nano.2011.05.016 ↗
29. Qu L, Peng X (2002) Control of photoluminescence properties of CdSe nanocrystals in growth. J Am Chem Soc 124:2049–205510.1021/ja017002j ↗
30. Sakamoto JH et al (2010) Enabling individualized therapy through nanotechnology. Pharmacol Res 62:57–89. doi: 10.1016/j.phrs.2009.12.01110.1016/j.phrs.2009.12.011 ↗
31. Sampath L, Kwon S, Hall MA, Price RE, Sevick-Muraca EM (2010) Detection of cancer metastases with a dual-labeled near-infrared/positron emission tomography imaging agent. Transl Oncol 3:30710.1593/tlo.10139 ↗
32. Saxena V, Sadoqi M, Shao J (2003) Degradation kinetics of indocyanine green in aqueous solution. J Pharm Sci 92:2090–2097. doi: 10.1002/jps.1047010.1002/jps.10470 ↗
33. Saxena V, Sadoqi M, Shao J (2006) Polymeric nanoparticulate delivery system for Indocyanine green: biodistribution in healthy mice. Int J Pharm 308:200–204. doi: 10.1016/j.ijpharm.2005.11.00310.1016/j.ijpharm.2005.11.003 ↗
34. Ventola CL (2012) The nanomedicine revolution: part 2: current and future clinical applications. P T 37:582–591
35. Villaraza AJ, Milenic DE, Brechbiel MW (2010) Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer. Bioconjug Chem 21:2305–2312. doi: 10.1021/bc100336b10.1021/bc100336b ↗
36. Wang ZY (2013) Near-infrared organic materials and emerging applications. CRC Press, Boca Raton, FL10.1201/b14775 ↗
37. Yoshida M et al (2012) Indocyanine green injection for detecting sentinel nodes using color fluorescence camera in the laparoscopy-assisted gastrectomy. J Gastroenterol Hepatol 27(Suppl 3):29–33. doi: 10.1111/j.1440-1746.2012.07067.x10.1111/j.1440-1746.2012.07067.x ↗
38. Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2:3–44. doi: 10.7150/thno.346310.7150/thno.3463 ↗